Compare Adaptive Biotechnologies Corp (ADPT) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs GSK plc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while GSK plc trades at $52.63 (market cap $105.91B). The key difference: GSK plc is far larger — about 31.8× Adaptive Biotechnologies Corp's market cap, and GSK plc pays a 3.38% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | GSK | |
|---|---|---|
Market Cap | $3.33B | $105.91B |
Sector | Health | Health |
52-Week High | $22.37 | $61.18 |
52-Week Low | $10.24 | $36.20 |
Enterprise Value | $3.19B | $126.53B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
GSK trades at $53.32, down 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $1.24 EPS, and maintains robust profitability with a 17.78% net income margin. Recent FDA approval for Utebzi and the $10.6 billion acquisition of Nuvalent highlight strategic expansion in oncology and anti-infectives.
Outlook remains positive with 7-9% EPS growth guidance for 2026, though risks include integration of large acquisitions and patent cliffs. Analyst consensus is mixed with 31% buy ratings, but solid fundamentals and recent approvals support a constructive view for long-term investors amid sector competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
